I have a list of 26 stocks that have joined the Dow Industrials since 1997. I looked at how those stocks performed after ...

Fastly (FSLY) stock has been one of the worst-performers this year as the company’s growth has decelerated and losses have ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

A certain %Mining company is finding a tremendous amount of success on Tuesday after the company reported a year-over-year increase in Q3 adjusted EBITDA results. While not a micro or small cap, ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Plus, options traders eye NVAX; CMI surges to fresh peak; and CE looks to extend losing streak.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...